CrawlingA developer of the non-invasive Brain computer Interface (BCI) technology, announced that BlackRock Neurotech, a company that implants BCIS, will offer the AXON-R Wearable Neural Interface platform for research institutions via the distribution network.
Blackrock Neurotech will act as an unlimited Axon-R from Cognixion, a non-invasive portable that makes exact measurement and modulation of brain activity possible via visual stimuli, biofeedback and neurofeedback.
AXON-R is a device for research quality that is exclusively intended for research use in neuroscience, educational use and neurorehabilitation. It is not deleted by the FDA for clinical or therapeutic applications.
In a statement, BlackRock Neurotech said that its core focus will remain on implantable, sovereign BCIs that restore speech, movement and sensation; However, it emphasizes that the availability of research quality tools, such as the AXON-R, opens the door for multidisciplinary innovation.
“This collaboration is a powerful coordination of complementary technologies that will have a major impact on neurotechnology applications,” said Andreas Forsland, CEO of Cognixion, in a statement.
“Blackrock Neurotech’s Implant Technology in combination with the AI and augmented reality platform from Cogixion will open new doors for both researchers and clinicians, while offering transformative solutions to the people we ultimately serve.”
Marcus Gerhardt, CEO of BlackRock Neurotech, said that the mission of his company is to restore the ability.
“By expanding access to research quality aids such as AXON-R, we want to support the early exploration of neural interfaces while maintaining our clinical focus on sovereign, high-fidelity implantable technologies that restore speech, movement and sensation,” Gerhardt said in a statement.
The larger trend
In March, Cognixion’s Forsland spoke with HIMSS TV About the use of augmented reality, AI and brain computer interface technologies to have patients with traumatic brain injury, strokes and as to communicate with the help of their eyes.
In 2024, Noldus information technology worked together with BlackRock Neurotech to integrate Noldus’ Ethovision XT behavioral following software with BlackRock’s electrophysiology systems, creating a uniform behavioral and neural research platform.
The integration makes real-time synchronization of the behavioral follow-up data of Ethovision XT possible with BlackRock’s EEG recordings for mice and rats.
The aim was to enable researchers to link real -time neural activity to behavioral results with greater accuracy and efficiency.
Other companies in the BCI room are located in New York Synchron, which announced this week that it will be the first BCI company that achieves native integration with Apple’s BCI Human Interface Device (BCI HID) profile.
The company’s technology is intended to enable people to manage digital devices, such as iPhones, iPads and Apple Vision Pro, with the help of their thoughts.
Earlier this month, Elon Musk’s Neuralink announced that it implanted his brain computer interface in a man named Brad Smith, who has as if it has and is completely non-verbal, so that he can now communicate with the help of telepathy.
Blacksmith a video released On X about his experience with Neuralink, which is told with the help of a replica generated by AI of Smith’s voice cloned from earlier recordings.
In March, Neuralink submitted applications to the US Patent and Trademark Office (USPTO) to act the conditions “Telepathy”, “Blindsight” and “Telekinese”.
The applications are related to the Neuralink offer. Telepathy is an interface of the brain computer that is aimed at enabling users to control devices with their thoughts, Blind is an implant that aims for the vision in people who are blind and Telekinese Is a term musk used interchangeably with telepathy to refer to controlling devices using a person’s mind.
Neuralink received last year Approval of Health Canada to perform a clinical test on its N1 brain implant and R1 robot, which is used to place the implant in the brain.
The “Canadian precise robotic implanted brain computer interface” (Can-Prime) study was conducted by the University Health Network Hospital in the Toronto Western Hospital.
Can-Prime assessed the safety of the company’s N1 implant, designed to enable individuals to control a computer or mobile device using their mind and the R1-surgical robot of the company, used to place each of the 64 threads of the N1 implant in the brains of a patient.
#Cogixion #BlackRock #Neurotech #partner #braincomputer #interface #technology